Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-05-15 4:04 pm Purchase |
2025-03-31 | 13G | Lyell Immunopharma, Inc. LYEL |
Foresite Capital Fund IV, L.P. | 1,358,095 9.200% |
384,150 (+39.44%) |
Filing History |
| 2025-02-14 4:55 pm Purchase |
2024-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
ARCH Venture Fund IX L.P. | 1,829,886 13.100% |
6,000 (+0.33%) |
Filing History |
| 2025-02-14 2:20 pm Purchase |
2024-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
Foresite Capital Fund IV, L.P. | 973,945 6.700% |
289,752 (+42.35%) |
Filing History |
| 2025-02-05 1:23 pm Sale |
2024-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
BlackRock Inc. BLK |
663,293 4.500% |
-51,818 (-7.25%) |
Filing History |
| 2024-11-12 4:04 pm Unchanged |
2024-09-30 | 13G | Lyell Immunopharma, Inc. LYEL |
The Vanguard Group | 503,574 3.930% |
0 (Unchanged) |
Filing History |
| 2024-11-04 1:30 pm Sale |
2024-09-30 | 13G | Lyell Immunopharma, Inc. LYEL |
The Vanguard Group | 503,574 3.930% |
-176,627 (-25.97%) |
Filing History |
| 2024-10-31 6:00 pm Purchase |
2024-10-25 | 13G | Lyell Immunopharma, Inc. LYEL |
Foresite Capital Fund IV, L.P. | 684,193 5.300% |
184,193 (+36.84%) |
Filing History |
| 2024-02-14 3:18 pm Purchase |
2023-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
ARCH Venture Fund IX L.P. | 1,823,886 14.500% |
3,250 (+0.18%) |
Filing History |
| 2024-02-13 5:08 pm Purchase |
2023-12-29 | 13G | Lyell Immunopharma, Inc. LYEL |
The Vanguard Group | 680,201 5.400% |
50,640 (+8.04%) |
Filing History |
| 2024-01-29 5:25 pm Purchase |
2023-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
BlackRock Inc. BLK |
715,111 5.700% |
715,111 (New Position) |
Filing History |
| 2023-02-13 5:02 pm Sale |
2022-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
Foresite Capital Fund IV, L.P. | 500,000 4.000% |
-164,109 (-24.71%) |
Filing History |
| 2023-02-09 11:25 am Purchase |
2022-12-30 | 13G | Lyell Immunopharma, Inc. LYEL |
The Vanguard Group | 629,562 5.050% |
629,562 (New Position) |
Filing History |
| 2022-02-14 4:17 pm Purchase |
2021-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
MWG Management Ltd. | 1,008,117 8.380% |
1,008,117 (New Position) |
Filing History |
| 2022-02-14 4:10 pm Purchase |
2021-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
NEWTON (PTC) Ltd | 754,698 6.280% |
754,698 (New Position) |
Filing History |
| 2022-02-14 12:04 pm Purchase |
2021-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
ARCH Venture Fund IX L.P. | 1,820,636 15.100% |
1,820,636 (New Position) |
Filing History |
| 2022-02-11 3:10 pm Purchase |
2021-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
Foresite Capital Fund IV, L.P. | 664,109 5.500% |
664,109 (New Position) |
Filing History |
| 2022-02-10 4:51 pm Purchase |
2021-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
GSK PLC | 1,512,659 12.600% |
1,512,659 (New Position) |
Filing History |